Assessment of Serum Chromogranin-A as Prognostic Factor in High-Risk Prostate Cancer

dc.creatorReis, LO
dc.creatorVieira, LFM
dc.creatorZani, EL
dc.creatorDenardi, F
dc.creatorde Oliveira, LC
dc.creatorFerreira, U
dc.date2010
dc.dateDEC
dc.date2014-07-30T13:51:09Z
dc.date2015-11-26T16:32:28Z
dc.date2014-07-30T13:51:09Z
dc.date2015-11-26T16:32:28Z
dc.date.accessioned2018-03-28T23:13:54Z
dc.date.available2018-03-28T23:13:54Z
dc.identifierJournal Of Investigative Medicine. Lippincott Williams & Wilkins, v. 58, n. 8, n. 957, n. 960, 2010.
dc.identifier1081-5589
dc.identifierWOS:000284490800017
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/55005
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/55005
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1270527
dc.descriptionPurpose: The presence of neuroendocrine differentiation may play a key role in androgen-independent tumor progression. The prognostic significance of plasma chromogranin-A (CgA) was assessed in a series of consecutive patients with high-risk prostate cancer (PCa). Patients and Methods: Twenty-three patients presenting high-risk PCa and 8 healthy individuals, as control group, had their blood samples collected to evaluate CgA, free and total prostate specific antigen, and free and total testosterone in a pilot study. The correlations of serum CgA levels with PSA, testosterone, Gleason score, number of foci of hypercaptation in bone scan, age, and outcomes were evaluated at baseline and after 12 months. Results: Patients with PCa had significantly higher levels of plasma CgA (mean, 8.7; range, 1.9-73) than healthy patients (mean, 3.45; range, 0.6-5.6), P = 0.02. Analyzing only the patients group through correlation of the ranks, it was observed that CgA has low, insignificant correlations with PSA (P = 0.07) and with metastatic extension (P = 0.09). No association was found between the plasma CgA levels and the Gleason score (P = 0.20), age (P = 0.15), or disease progression (P = 0.27). Conclusion: The serum levels of CgA were significantly increased in the group with PCa compared with the healthy group. However, there were low correlations between serum CgA and known prognostic factors (such as total and free PSA, age, Gleason score, and bone metastases) or clinical deterioration. Although future studies are needed with larger samples and longer follow-up, the presented data envisage a limited role to serum CgA as high-risk PCa prognostic factor.
dc.description58
dc.description8
dc.description957
dc.description960
dc.descriptionFoundation to Support Education, Research and Extension (FAEPEX)
dc.descriptionInstitutional Program for Scientific Initiation (PIBIC)
dc.languageen
dc.publisherLippincott Williams & Wilkins
dc.publisherPhiladelphia
dc.publisherEUA
dc.relationJournal Of Investigative Medicine
dc.relationJ. Invest. Med.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectserum
dc.subjectchromogranin-A
dc.subjectprognostic factor
dc.subjecthigh risk
dc.subjectprostate cancer
dc.subjectPSA
dc.subjectGleason
dc.subjectneuroendocrine
dc.subjectmetastasis
dc.subjecttestosterone
dc.subjectAndrogen Deprivation Therapy
dc.subjectHormone-refractory Disease
dc.subjectNeoplastic Human Prostate
dc.subjectNeuroendocrine Differentiation
dc.subjectEndocrine Therapy
dc.subjectReceptor Status
dc.subjectCells
dc.subjectCarcinoma
dc.subjectMarkers
dc.subjectProliferation
dc.titleAssessment of Serum Chromogranin-A as Prognostic Factor in High-Risk Prostate Cancer
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución